PL2313087T3 - Farmaceutyczna postać dawkowania do natychmiastowego uwalniania pochodnej indolinonu - Google Patents

Farmaceutyczna postać dawkowania do natychmiastowego uwalniania pochodnej indolinonu

Info

Publication number
PL2313087T3
PL2313087T3 PL09757601T PL09757601T PL2313087T3 PL 2313087 T3 PL2313087 T3 PL 2313087T3 PL 09757601 T PL09757601 T PL 09757601T PL 09757601 T PL09757601 T PL 09757601T PL 2313087 T3 PL2313087 T3 PL 2313087T3
Authority
PL
Poland
Prior art keywords
dosage form
pharmaceutical dosage
immediate release
indolinone derivative
indolinone
Prior art date
Application number
PL09757601T
Other languages
English (en)
Other versions
PL2313087T5 (pl
Inventor
Roman Messerschmid
Peter Lach
Torsten Sokoliess
Peter Stopfer
Dirk Trommeshauser
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41017080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2313087(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PL2313087T3 publication Critical patent/PL2313087T3/pl
Publication of PL2313087T5 publication Critical patent/PL2313087T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Business, Economics & Management (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Educational Administration (AREA)
  • Educational Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL09757601.1T 2008-06-06 2009-06-04 Farmaceutyczna postać dawkowania do natychmiastowego uwalniania pochodnej indolinonu PL2313087T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08157750 2008-06-06
EP09757601.1A EP2313087B2 (en) 2008-06-06 2009-06-04 Pharmaceutical dosage form for immediate release of an indolinone derivative
PCT/EP2009/056895 WO2009147220A1 (en) 2008-06-06 2009-06-04 Pharmaceutical dosage form for immediate release of an indolinone derivative

Publications (2)

Publication Number Publication Date
PL2313087T3 true PL2313087T3 (pl) 2019-05-31
PL2313087T5 PL2313087T5 (pl) 2024-03-04

Family

ID=41017080

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09757601.1T PL2313087T5 (pl) 2008-06-06 2009-06-04 Farmaceutyczna postać dawkowania do natychmiastowego uwalniania pochodnej indolinonu

Country Status (35)

Country Link
US (3) US20110190318A1 (pl)
EP (1) EP2313087B2 (pl)
JP (2) JP5583119B2 (pl)
KR (1) KR20110022586A (pl)
CN (1) CN102056599A (pl)
AR (1) AR072060A1 (pl)
AU (1) AU2009254556B2 (pl)
BR (1) BRPI0913235A2 (pl)
CA (1) CA2726648A1 (pl)
CL (1) CL2010001362A1 (pl)
CO (1) CO6280468A2 (pl)
CY (1) CY1121272T1 (pl)
DK (1) DK2313087T4 (pl)
EA (1) EA201001857A1 (pl)
EC (1) ECSP10010717A (pl)
ES (1) ES2711913T5 (pl)
FI (1) FI2313087T4 (pl)
HR (1) HRP20190181T4 (pl)
HU (1) HUE042524T2 (pl)
IL (1) IL209055A0 (pl)
LT (1) LT2313087T (pl)
MA (1) MA32386B1 (pl)
MX (1) MX338001B (pl)
PE (1) PE20100050A1 (pl)
PL (1) PL2313087T5 (pl)
PT (1) PT2313087T (pl)
RS (1) RS58280B2 (pl)
SG (1) SG191607A1 (pl)
SI (1) SI2313087T2 (pl)
TR (1) TR201901579T4 (pl)
TW (1) TW201002692A (pl)
UA (1) UA107560C2 (pl)
UY (1) UY31876A (pl)
WO (1) WO2009147220A1 (pl)
ZA (1) ZA201007972B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
UA104590C2 (ru) * 2008-06-06 2014-02-25 Берингер Ингельхайм Интернациональ Гмбх Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
JP2015532272A (ja) 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN105377965B (zh) 2013-06-04 2019-05-10 蒙诺苏尔有限公司 水溶性膜密封溶液、相关方法和相关物品
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
KR20260025887A (ko) 2015-06-06 2026-02-24 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
AU2017274195B2 (en) 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
CN110573161A (zh) * 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
IL273169B2 (en) 2017-10-23 2024-05-01 Boehringer Ingelheim Int New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
US20230135671A1 (en) 2020-04-01 2023-05-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN119630398A (zh) 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PT1948180E (pt) * 2005-11-11 2013-05-10 Boehringer Ingelheim Int Tratamento de combinação de cancro compreendendo inibidores de egfr/her2
ME02273B (me) * 2008-06-06 2016-02-20 Boehringer Ingelheim Int Farmaceutska kombinacija
UA104590C2 (ru) * 2008-06-06 2014-02-25 Берингер Ингельхайм Интернациональ Гмбх Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
US20120157472A1 (en) * 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
US20120142703A1 (en) * 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases

Also Published As

Publication number Publication date
ZA201007972B (en) 2011-07-27
IL209055A0 (en) 2011-01-31
DK2313087T3 (en) 2019-02-18
MA32386B1 (fr) 2011-06-01
HRP20190181T1 (hr) 2019-03-22
MX338001B (es) 2016-03-30
JP5992937B2 (ja) 2016-09-14
ES2711913T3 (es) 2019-05-08
UA107560C2 (uk) 2015-01-26
EP2313087B2 (en) 2023-11-22
SG191607A1 (en) 2013-07-31
KR20110022586A (ko) 2011-03-07
HRP20190181T4 (hr) 2024-07-05
SI2313087T1 (sl) 2019-03-29
CL2010001362A1 (es) 2011-05-13
RS58280B2 (sr) 2024-02-29
MX2010013092A (es) 2011-02-25
US20130203773A1 (en) 2013-08-08
PL2313087T5 (pl) 2024-03-04
SI2313087T2 (sl) 2024-03-29
WO2009147220A1 (en) 2009-12-10
PT2313087T (pt) 2019-02-15
AR072060A1 (es) 2010-08-04
JP2011522010A (ja) 2011-07-28
US20140163040A1 (en) 2014-06-12
EP2313087B1 (en) 2018-11-21
TR201901579T4 (tr) 2019-02-21
FI2313087T4 (fi) 2023-12-28
DK2313087T4 (da) 2024-01-15
EP2313087A1 (en) 2011-04-27
CA2726648A1 (en) 2009-12-10
CY1121272T1 (el) 2020-05-29
CO6280468A2 (es) 2011-05-20
ES2711913T5 (es) 2024-06-24
UY31876A (es) 2010-01-29
JP5583119B2 (ja) 2014-09-03
TW201002692A (en) 2010-01-16
HUE042524T2 (hu) 2019-07-29
ECSP10010717A (es) 2011-02-28
JP2014098045A (ja) 2014-05-29
PE20100050A1 (es) 2010-01-29
RS58280B1 (sr) 2019-03-29
AU2009254556B2 (en) 2015-08-20
LT2313087T (lt) 2019-02-25
CN102056599A (zh) 2011-05-11
AU2009254556A1 (en) 2009-12-10
BRPI0913235A2 (pt) 2016-01-19
EA201001857A1 (ru) 2011-06-30
US20110190318A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
ZA201007972B (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
ZA201007636B (en) Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
ZA201102406B (en) Pharmaceutical composition for modified release
IL207512A0 (en) Pharmaceutical composition for poorly soluble drugs
IL214628A0 (en) Sustained release oral dosage forms of an r- baclofen prodrug
IL213545A0 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
IL213546A0 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
ZA201105572B (en) Pharmaceutical composition for oral administration
ZA200810178B (en) Pharmaceutical compositions for sustained release of phenyephrine
ZA201101053B (en) Pharmaceutical compositions of samatotrophic hormones
LT2391352T (lt) Farmacinės veikliųjų medžiagų atpalaidavimo formos
EP2343076A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
GB0802873D0 (en) Pharmaceutical dosage forms for delayed and extended release
SMT202100059T1 (it) Composizione farmaceutica per il rilascio modificato
HK1164734A (en) Sustained release oral dosage forms of an r-baclofen prodrug
ZA201001127B (en) Pharmaceutical formulation for extended release